Tris Pharma has announced partnerships with Calm Health and ADHD Central to provide digital mental health resources and practical organisation tools for people living with attention-deficit/hyperactivity disorder (ADHD).

The partnerships will support eligible patients starting treatment with DYANAVEL XR, Tris Pharma’s long-acting ADHD medicine approved for people aged six years and older.

As part of the agreement with Calm Health, eligible new DYANAVEL XR patients will receive three months of complimentary access to the digital mental health platform.

Calm Health provides personalised programmes and self-care resources, including ADHD-focused content intended to support healthy habits and self-management.

Digital resources for ADHD care

Tris Pharma said the partnerships are intended to provide resources that complement prescription treatment and address some of the practical and mental health challenges associated with living with ADHD.

Manesh Naidu, chief commercial officer at Tris Pharma, said: “Effective ADHD management often requires more than medication alone.”

He added: “By partnering with Calm Health and ADHD Central, we hope to provide patients access to tools that may help support both their mental well-being and their daily organization.”

The Calm Health platform includes programmes focused on areas such as emotional wellbeing, healthy habits and self-management. Its ADHD-specific resources are designed to help users navigate aspects of everyday life associated with the condition.

The partnership gives eligible patients access to the platform when they begin treatment with DYANAVEL XR, providing a digital resource alongside their prescribed medicine.

ADHD Central provides practical tools

Tris Pharma is also partnering with ADHD Central, which develops screen-free and visual organisation tools for people with ADHD.

The company’s products include ON TRACK Cards, a visual task-management system designed to help users organise daily responsibilities without relying on digital devices.

Through the partnership, Tris Pharma will connect patients and caregivers with ADHD Central’s resources, which are intended to support organisation, focus and routine-building.

The initiative takes a different approach from the Calm Health partnership by focusing on practical tools for managing everyday activities rather than digital mental health resources.

Together, the partnerships give Tris Pharma two additional ways to support patients and caregivers alongside conventional ADHD treatment.

Support beyond prescription treatment

Tris Pharma said the partnerships form part of its wider approach to supporting people with ADHD, including those whose symptoms are not adequately managed.

The company has five FDA-approved ADHD products and markets DYANAVEL XR as a long-acting treatment for ADHD in people aged six years and older.

The new partnerships do not change the approved indication for DYANAVEL XR. Instead, they provide additional resources for eligible patients beginning treatment.

The initiative reflects a broader focus within ADHD care on supporting patients with the practical and behavioural challenges that can accompany the condition, alongside pharmacological treatment.

For Tris Pharma, the collaborations also extend its involvement in ADHD care beyond the prescription itself, bringing digital mental health and non-digital organisational resources into the treatment experience.